Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$68.70 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.07M
Market Cap
$12.95B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.22B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 07, 2025EPS Estimate
1.01Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding158,300,000
10 Day Avg. Volume1,991,346
30 Day Avg. Volume2,074,231
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)4.69
Price to Sales (P/S)0.00
P/FCF Ratio18.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$107.13Price Target Upside28.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Illumina News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIllumina reported 1Q revenues of $1.04B slightly above the Street of $1.03B.
Market PositionILMN's core ~60% consumable clinical customer mix is seen as defensible despite an increasingly tougher market backdrop.
Operational EfficiencyA cost reduction program of $100M is expected to phase in this year, partly mitigating tariff impacts.
Bears Say
CompetitionCompetition from Roche is considered a more meaningful risk for ILMN.
Export RestrictionsExport of ILMN instruments was banned after the company was put on the Unreliable Entity List.
Revenue ExpectationsThe company decreased its 2025 guidance for non-GAAP diluted EPS further, reflecting lower revenue expectations due to the challenges faced in China and tariff impacts.
Ownership Overview
2.69% Insiders
30.44% Mutual Funds
41.90% Other Institutional Investors
2.39% Public Companies and Individual Investors
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $12.95B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Aug 07, 2025 which is in 62 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on May 08, 2025. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of $3.104 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.01.
How many shares outstanding does Illumina have?
Illumina has 158,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $0.97 in its last earnings report, beating expectations of $0.94. Following the earnings report the stock price went down -4.8%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$107.13 (28.82% Upside)
$107.13 (28.82% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.15%
12-Months-Change
Fundamentals
Return on Equity
-23.82%
Trailing 12-Months
Asset Growth
-38.43%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. is a leading biotechnology company that specializes in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company primarily operates in the genomics sector, providing innovative sequencing and array-based solutions that are used in a variety of applications including genetic research, clinical diagnostics, agriculture, and forensics. Illumina's core products include sequencing systems, consumables, and software that support researchers and clinicians in their pursuit of groundbreaking discoveries and advancements in personalized medicine.
ILMN Company Deck
ILMN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong performance in certain areas like NovaSeq X placements and innovation pipeline advancements, but significant challenges in the Greater China region, research funding uncertainty, and tariff impacts. While growth areas show promise, the lowlights pose substantial risks.Read More>ILMN Revenue Breakdown
91.33% Sequencing
8.67% Microarray
ILMN Stock 12 Month Forecast
Average Price Target
$107.13
▲(28.82%Upside)